Stevanato Group (STVN) Investor presentation summary

Operational excellence and market leadership

• Over 70 years, established as a leading provider of mission-critical solutions for the biopharma industry, serving 23 of the top 25 pharma companies and achieving a 13% revenue CAGR from FY19 to FY25.

• Global footprint with 13 production sites and ongoing investments to expand capacity and ensure supply security.

• Integrated offering across drug containment, delivery systems, and engineering, with a unique value proposition and strong customer partnerships.

• High-value solutions (HVS) now represent 46% of FY25 revenue, up from 17% in FY19, driving margin expansion.

• Recognized for sustainability, ranking in the top 15% by Ecovadis in 2025.

Financial performance and guidance

• FY25 revenue reached €1,186M, with adjusted EBITDA margin at 25.1% despite temporary inefficiencies.

• Q1 2026 revenue grew 7% year-over-year to €274M, with HVS revenue up 17% and representing 47% of total revenue.

• Gross profit margin in Q1 2026 increased to 27.5%, and adjusted EBITDA margin rose to 23.9%.

• FY26 revenue guidance is €1.26B–€1.29B (6–9% growth), with adjusted EBITDA expected to grow 11–16% and HVS to comprise 47–48% of revenue.

• CapEx remains focused on growth, with 89% of FY25 CapEx tied to expansion and a target to normalize CapEx at ~20% of revenue.

Strategic priorities and growth drivers

• Positioned to benefit from secular trends: aging populations, growth in biologics, expanded healthcare access, and self-administration of medicines.

• Biologics are the primary growth driver, with GLP1s accounting for 19–22% of revenue and non-GLP biologics also expanding.

• Multi-year innovation pipeline and global expansion support sustainable organic growth and margin improvement.

• Engineering optimization plan underway to improve cost structure and drive new order intake, especially in Denmark.

• Return on invested capital expected to grow from 2025 as new capacity comes online and temporary inefficiencies abate.